Ed Silverman at Pharmalot says that NIH has responded to reports of NIH-funded investigators using ghostwriting firms by strengthening a conflict of interest rule, but he adds that move might not be going far enough.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.